Balaglitazone: A Second Generation Peroxisome Proliferator-Activated Receptor (PPAR) Gamma (&ggr;) Agonist

E-ISSN： 1875-5607|12|2|87-97

ISSN： 1389-5575

Source： Mini Reviews in Medicinal Chemistry, Vol.12, Iss.2, 2012-02, pp. : 87-97

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Agonist of peroxisome proliferator-activated receptor gamma (PPAR-  ): a new compound with potent gastroprotective and ulcer healing properties

By Brzozowski Tomasz

Inflammopharmacology, Vol. 13, Iss. 1-3, 2005-08 ,pp. : 317-330

VSP

Access to resources Recommend Favorite

Peroxisome Proliferator-Activated Receptor (PPAR)&bgr; /&dgr;: A New Potential Therapeutic Target for the Treatment of Metabolic Syndrome

Current Molecular Pharmacology, Vol. 2, Iss. 1, 2009-01 ,pp. : 46-55

Bentham Science Publishers

Access to resources Recommend Favorite

The Need for Physiologically Relevant Peroxisome Proliferator-Activated Receptor-gamma (PPAR-γ) Ligands

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 13, Iss. 2, 2013-06 ,pp. : 175-183

Bentham Science Publishers

Access to resources Recommend Favorite

Peroxisome Proliferator-Activated Receptor (PPAR) Gamma Agonists as Therapeutic Agents for Cardiovascular Disorders: Focus on Atherosclerosis

Current Pharmaceutical Design, Vol. 23, Iss. 7, 2017-04 ,pp. : 1119-1124

Bentham Science Publishers

Access to resources Recommend Favorite

Peroxisome Proliferator-Activated Receptor (PPAR)-α: A Pharmacological Target with a Promising Future

By van Raalte Daniel H. Li Min Pritchard P. Haydn Wasan Kishor M.

Pharmaceutical Research, Vol. 21, Iss. 9, 2004-09 ,pp. : 1531-1538

Springer Publishing Company

Access to resources Recommend Favorite